Showing 5291-5300 of 8126 results for "".
- Three New CeraVe Baby Products Awarded National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/three-new-cerave-baby-products-awarded-national-eczema-association-seal-of-acceptance/2458995/Valeant Pharmaceuticals North America LLC is pleased to announce today that all three products in its newest product line, CeraVe® Baby, have been awarded the National Eczema Association (NEA) Seal of Acceptance™, which maintains rigorous standards for approval. Products include Ce
- Promius Pharma, LLC to Market, Distribute Trianex 0.05%https://practicaldermatology.com/news/promius-pharma-llc-to-market-distribute-trianex-005/2458997/Promius Pharma, LLC, has acquired the rights to market and distribute Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc. Trianex Ointment, a mid-potency corticosteroid, is notable for its white formulation that has the look and feel of
- Investigational Atopic Dermatitis Cream Disappoints in Phase II Trialhttps://practicaldermatology.com/news/investigational-atopic-dermatitis-cream-disappoints-in-phase-ii-trial/2459003/Results from a phase II trial do not bode well for the future of the investigational atopic dermatitis cream MRX-6. The double-blind, parallel-group, vehicle-controlled study evaluated the safety and efficacy of MRX-6 cream 2% among 73 children suffering from mild-to-moderate atopic dermatitis. P
- Kythera Acquires Rights to Experimental Hair Loss Treatmenthttps://practicaldermatology.com/news/kythera-acquires-rights-to-experimental-hair-loss-treatment/2459008/Kythera Biopharmaceuticals has struck two separate license agreements with Actelion Pharmaceuticals and the University of Pennsylvania for a potential novel treatment of hair loss. In the agreement with Actelion, Kythera gained licensing of the worldwide rights to setipiprant, a clinical-stage se
- InMed Initiates Program Targeting Epidermolysis Bullosa Simplexhttps://practicaldermatology.com/news/inmed-initiates-program-targeting-epidermolysis-bullosa-simplex/2459014/InMed Pharmaceuticals Inc. added a new therapy to its pipeline: INM-750, for the treatment of Epidermolysis bullosa simplex(EBS), a rare genetically inherited skin disorder. INM-750 is designed to suppress pathological skin growth, differentiation, and inflammation that are signature characterist
- Galderma Launches Restylane Silk for Lip Enhancement and Treatment of Perioral Lineshttps://practicaldermatology.com/news/galderma-launches-restylane-silk-for-lip-enhancement-and-treatment-of-perioral-lines/2459015/Galderma launched Restylane® Silk, the first and only dermal filler FDA approved for lip enhancement and the treatment of wrinkles and lines around the mouth in people over the age of 21. Restylane Silk is a smooth gel designed to restore natural youthful definitio
- Aclaris Therapeutics Announces Positive Results from Phase IIb Trial of A-101 for the Removal of Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-announces-positive-results-from-phase-iib-trial-of-a-101-for-the-removal-of-seborrheic-keratosis/2459016/Aclaris Therapeutics, Inc. announced positive results from a Phase IIb clinical trial of the Company’s lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing multiple seborrheic keratoses (SK). Though the lesions are benign, many
- Celsus Therapeutics Receives FDA Allowance of IND in Atopic Dermatitishttps://practicaldermatology.com/news/celsus-therapeutics-receives-fda-allowance-of-ind-in-atopic-dermatitis/2459026/Celsus Therapeutics will expand its clinical program in atopic dermatitis in the US, now that the FDA has allowed its Investigational New Drug Application (IND) for the clinical development of MRX-6 Cream 2% in patients with atopic dermatitis. The Com
- XTRAC Offering Rebate for Excimer Laser Treatmentshttps://practicaldermatology.com/news/xtrac-offers-coupon-for-vitiligo-treatments/2459029/PhotoMedex is offering a limited-time rebate for patients treated with the XTRAC Excimer Laser from January 1 through March 31, 2015. The rebate is worth up to $100 per treatment and can be used to offset the costs of insurance deduc
- Suneva Medical's Bellafill Approved to Treat Acne Scarshttps://practicaldermatology.com/news/suneva-medicals-bellafill-approved-to-treat-acne-scars/2459034/Suneva Medical, Inc.'s Bellafill® is now the only filler on the market approved for the treatment of acne scars. FDA granted approval for Bellafil